Strong Financial Performance in Fiscal 2025
Cencora achieved a 16% growth in adjusted operating income and adjusted diluted EPS, driven by strategic positioning in Specialty and strong pharmaceutical utilization trends.
Raised Long-term Guidance
Cencora raised its long-term guidance for adjusted operating income growth to 6% to 9% and adjusted EPS growth to 9% to 13%.
Significant Investments in Infrastructure
Announced a $1 billion investment through 2030 to amplify distribution network, including opening a second National Distribution Center and expanding existing specialty distribution capacity.
Strong Performance in Specialty
Consolidated gross profit was $2.9 billion, up 18%, driven largely by the contribution from the acquisition of Retina Consultants of America.
U.S. Healthcare Solutions Segment Growth
U.S. Healthcare Solutions segment operating income increased by 25% to $872 million due to growth across distribution businesses and the contribution from Retina Consultants of America.